Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cure Rare Disease, Inc
With
University of Massachusetts, Worcester
The objective of the study is to assess the safety and preliminary efficacy of CRD-TMH-001 after intravenous administration for a period of 1 year with long-term follow-up out to 15 years.
Age
18–28
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Completion of informed consent
Confirmation of genetic mutation
Confirmation of absence of elevated AAV9 NAbs
You may not be if
\- Any significant medical issue(s) (past or current) that would, in the opinion of the Principal Investigator (PI), prevent this patient from being dosed.